Lupin is currently trading at Rs. 634.70, up by 57.90 points or 10.00% from its previous closing of Rs. 579.20 on the BSE.
The scrip opened at Rs. 580.30 and has touched a high and low of Rs. 637.10 and Rs. 578.60 respectively. So far 48069 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 637.10 and Rs. 536.80 respectively. The current market cap of the company is Rs. 27859.38 crore.
The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad, India facility. The inspection for the facility was carried out by the USFDA between February 10, 2020 and February 14, 2020 and concluded with no observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.